Genmab — September 2017
-
Ja troede os vi ville få en pæn stigning idag, men meget er jo indregnet i nuværende kurs.
-
https://www.ncbi.nlm.nih.gov/pubmed/28544069 Lidt mere om cd38 og cervical
-
@Bulder/Solsen Har lige lavet et fint lille regneark med alle kendte JnJ Q/
Y salgstal. Dit bud på Q3 (260+140) er da pænt friskt: det svarer til 23% vækst i US og 61% vækst i ROW ift. Q2. Hvis vi, bår' for sjow, fortsætter vækstantagelsen gennem Q4, ender vi med 2017Y: 991US + 507ROW = 1497 ($M). Dette svarer til 9300 Mkr ~ 1110 Mkr i royalt (12%) og vil kunne udvirke en opdatering på ~150 Mkr. (GENs forventninger er pt. 1100-1300 $M ~ 8000 Mkr (high end) ~ 970 Mkr royalt (12%).)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind